Research progress on latent tuberculosis infection

doi:10.3969/j.issn.2096-8493.2020.01.017

Abstract

Abstract:

Latent tuberculosis infection is a hotspot in the field of tuberculosis control. There is a large number of people with latent tuberculosis infection in the world and in China, so many issues are still worthy to be paid further attentions, such as the policies on screening of the key populations and management of the people with latent tuberculosis infection in different countries, interpretation of the screening results, identification of people who need prophylactic medication, evaluation of treatment effects and the progress of vaccine research and development, etc. The author conducted review and exploration in terms of the above issues so as to provide academic reference for the related follow-up researches.

Key words: Latent tuberculosis, Health policy, Protective agents, Vaccines, Review

YAO Jing, GU Kai-kan, LI Zhi-hong, HAN Zhi-ying, ZHANG Huai-qing. Research progress on latent tuberculosis infection[J]. Journal of Tuberculosis and Lung Disease , 2020, 1(1): 82-88. doi: 10.3969/j.issn.2096-8493.2020.01.017

Figures/Tables 3

References 71

[1]	World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
[2]	中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09.
[3]	Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ, 2018,362:k2738. doi: 10.1136/bmj.k2738.
[4]	Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol, 1974,99(2):131-138. doi: 10.1093/oxfordjournals.aje.a121593. doi: 10.1093/oxfordjournals.aje.a121593 URL pmid: 4810628
[5]	Gao L, Li X, Liu J, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural china: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2017,17(10):1053-1061. doi: 10.1016/S1473-3099(17)30402-4. URL pmid: 28716677
[6]	Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016,13(10):e1002152. doi: 10.1371/journal.pmed.1002152.
[7]	全国结核病流行病学抽样调查技术指导组. 第四次全国结核病流行病学抽样调查报告. 中华结核和呼吸杂志, 2002,25(1):3-7. doi: 10.3760/j:issn:1001-0939.2002.01.002.
[8]	刘贤政, 周青阳, 马世海, 等. 某区部队结核菌素试验普查分析. 解放军预防医学杂志, 2004,22(4):305. doi: 10.3969/j.issn.1001-5248.2004.04.031.
[9]	He GX, van denHof S, van der Werf MJ, et al. Infection control and the burden of tuberculosis infection and disease in health care workers in China: a cross-sectional study. BMC Infect Dis, 2010,10:313. doi: 10.1186/1471-2334-10-313. URL pmid: 21029452
[10]	Zhang X, Jia H, Liu F, et al. Prevalence and Risk Factors for Latent Tuberculosis Infection Among Health Care Workers in China: A Cross-Sectional Study. PLoS One, 2013,8(6):e66412. doi: 10.1371/journal.pone.0066412. doi: 10.1371/journal.pone.0066412 URL pmid: 23823871
[11]	Zhang LF, Liu XQ, Zhang Y, et al. A prospective longitudinal study evaluating a t-cell-based assay for latent tuberculosis infection in health-care workers in a general hospital in Beijing. Chin Med J (Engl), 2013,126(11):2039-2044.
[12]	林涛, 胡屹, 侯云, 等. 上海地区四小学高年级学生结核感染率及影响因素的横断面研究. 中华传染病杂志, 2011,29(3):148-153. doi: 10.3760/cma.j.issn.1000-6680.2011.03.005.
[13]	Hu Y, Zhao Q, Wu L, et al. Prevalence of latent tuberculosis infection and its risk factors in schoolchildren and adolescents in Shanghai, China. Eur J Public Health, 2013,23(6):1064-1069. doi: 10.1093/eurpub/ckt105. doi: 10.1093/eurpub/ckt105 URL
[14]	郭建丽, 徐勤, 刘玉清. 北京市海淀区33所大学新生的结核感染状况调查. 中华预防医学杂志, 2006,40(5):355-358. doi: 10.3760/j:issn:0253-9624.2006.05.013.
[15]	陈莉莉, 郭俊涛, 李朋, 等. 上海市浦东新区大中专院校肺结核患者学生密切接触者结核潜隐感染现状及影响因素分析. 上海预防医学, 2018,30(3):165-169, 175. doi: 10.19428/j.cnki.sjpm.2018.18660.
[16]	Hu Y, Zhao Q, Graviss EA, et al. Use of the T-SPOT.TB assay to screen latent tuberculosis infection among the TB contacts in Shanghai, China. J Infect, 2012,65(1):39-48. doi: 10.1016/j.jinf.2012.03.018.
[17]	王海英, 蒋彩花, 王俊玲, 等. 山东省某监狱劳教人员结核病筛查结果分析. 中国防痨杂志, 2009,31(6):327-330.
[18]	Li X, Yang Q, Feng B, et al. Tuberculosis infection in rural labor migrants in Shenzhen, China: Emerging challenge to tuberculosis control during urbanization. Sci Rep, 2017,7(1):4457. doi: 10.1038/s41598-017-04788-1.
[19]	Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2015,15(3):310-319. doi: 10.1016/S1473-3099(14)71085-0.
[20]	张馨赟, 高岩, 邵凌云, 等. 云南和上海两地人类免疫缺陷病毒感染者合并潜伏性结核分枝杆菌感染情况. 中华传染病杂志, 2014,32(10):585-588. doi: 10.3760/cma.j.issn.1000-6680.2014.10.003
[21]	唐佩军, 吴妹英. 结核分枝杆菌感染免疫应答与免疫逃逸机制的研究进展. 结核病与肺部健康杂志, 2017,6(2):181-186. doi: 10.3969/j.issn.2095-3755.2017.02.022.
[22]	金鹏锋, 陈琳, 胡耀仁. T细胞耗竭在结核分枝杆菌感染中的作用. 中华医院感染学杂志, 2019,29(12):1917-1920. doi: 10.11816/cn.ni.2019-184104.
[23]	沈洪波, 陈维政. 结核分枝杆菌潜伏感染的免疫机制及免疫干预研究进展. 中华结核和呼吸杂志, 2016,39(1):47-51. doi: 10.3760/cma.j.issn.1001-0939.2016.01.013.
[24]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[25]	Jagger A, Reiter Karam S, Hamada Y, et al. National policies on the management of latent tuberculosis infection: review of 98 countries. Bull World Health Organ, 2018,96(3):173-184F. doi: 10.2471/BLT.17.199414.
[26]	Centers for Disease Control and Prevention. Tuberculosis is progressing now [EB/OL]. [2020-03-05]. http://cdc.go.kr/CDC/intro/CdcKrIntro0505.jsp?menuIds=HO ME001-MNU1154-MNU2557-MNU2487&fid=7947&cid=73871 (Korean).
[27]	Kawatsu L, Uchimura K, Ohkado A. Trend and treatment status of latent tuberculosis infection patients in Japan-Analysis of Japan TB Surveillance data. PLoS One, 2017,12(11):e0186588. doi: 10.1371/journal.pone.0186588.
[28]	Prevention Committee of the Japanese Society for Tuberculosis, Treatment Committee of the Japanese Society for Tuberculosis. Treatment guidelines for latent tuberculosis infection. Kekkaku, 2014,89(1):21-37. URL pmid: 24654427
[29]	Mancuso JD, Diffenderfer JM, Ghassemieh BJ, et al. The Prevalence of Latent Tuberculosis Infection in the United States. Am J Respir Crit Care Med, 2016,194(4):501-509. doi: 10.1164/rccm.201508-1683OC. doi: 10.1164/rccm.201508-1683OC URL pmid: 26866439
[30]	Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000,49(RR-6):1-51. URL pmid: 10881762
[31]	中华人民共和国国家卫生和计划生育委员会,中华人民共和国教育部学校结核病防控工作规范(2017版). 国卫办疾控发[2017] 22号. 2017-06-26.
[32]	Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep, 2005,54(RR-15):49-55.
[33]	Gao L, Jin Q. Differences in BCG vaccination and tuberculin skin-test positivity—Authors’ reply. Lancet Infect Dis, 2015,15(9):1003-1003. doi: 10.1016/S1473-3099(15)00251-0.
[34]	李相威, 金奇, 高磊. 我国结核分枝杆菌潜伏感染流行现状. 新发传染病电子杂志, 2017,2(3):146-150. doi: 10.3877/j.issn.2096-2738.2017.03.006.
[35]	赵静. 校园潜伏结核感染的筛查. 济南: 山东省医学科学院, 2009: 1-66.
[36]	Muñoz L, Stagg HR, Abubakar I. Diagnosis and Management of Latent Tuberculosis Infection. Cold Spring Harb Perspect Med, 2015,5(11):a017830. doi: 10.1101/cshperspect.a017830. doi: 10.1101/cshperspect.a017830 URL pmid: 26054858
[37]	Tasillo A, Salomon JA, Trikalinos TA, et al. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States with and without Medical Comorbidities in a Simulation Model. JAMA Intern Med, 2017,177(12):1755-1764. doi: 10.1001/jamainternmed.2017.3941. doi: 10.1001/jamainternmed.2017.3941 URL pmid: 29049814
[38]	Campbell JR, Johnston JC, Cook VJ, et al. Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. Emerg Infect Dis, 2019,25(4):661-671. doi: 10.3201/eid2504.171630. doi: 10.3201/eid2504.171630 URL pmid: 30882302
[39]	Toru Mori. 日本结核病接触调查中存在的问题. 中国防痨杂志, 2017,39(1):22-27. doi: 10.3969/j.issn.1000-6621.2017.01.008.
[40]	Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med, 2017,5(4):259-268. doi: 10.1016/S2213-2600(16)30436-2. doi: 10.1016/S2213-2600(16)30436-2 URL pmid: 28159608
[41]	Starshinova A, Zhuravlev V, Dovgaluk I, et al. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. Int J Mycobacteriol, 2018,7(1):32-39. doi: 10.4103/ijmy.ijmy_17_18. doi: 10.4103/ijmy.ijmy_17_18 URL pmid: 29516883
[42]	中华人民共和国国务院办公厅. “十三五”全国结核病防治规划. 国办发〔2017〕16号. 2017-02-16.
[43]	中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. γ-干扰素释放试验在中国应用的建议. 中华结核和呼吸杂志, 2014,37(10):744-747. doi: 10.3760/cma.j.issn.1001-0939.2014.10.011.
[44]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09.
[45]	刘二勇, 周林, 成诗明. 结核分枝杆菌潜伏性感染及预防性治疗研究进展的系统评价. 中国防痨杂志, 2013,35(4):231-239.
[46]	宋其生. IGRA在结核诊断与治疗中的应用研究. 大连: 大连医科大学, 2012: 1-86.
[47]	Menzies D, Gardiner G, Farhat M, et al. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis, 2008,12(5):498-505. URL pmid: 18419884
[48]	中华人民共和国国家卫生健康委员会办公厅. 中国结核病预防控制工作技术规范(2020年版). 国卫办疾控函〔2020〕279号. 2020-04-02.
[49]	Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep, 2020,69(1):1-11. doi: 10.15585/mmwr.rr6901a1. doi: 10.15585/mmwr.rr6901a1 URL pmid: 32053584
[50]	上海市防痨协会,中国防痨协会青年理事会, 《中国防痨杂志》编辑委员会. 学校结核病疫情流行病学调查和现场处置专家共识. 中国防痨杂志, 2019,41(1):9-13. doi: 10.3969/j.issn.1000-6621.2019.01.004.
[51]	Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev, 2014,27(1):3-20. doi: 10.1128/CMR.00034-13. doi: 10.1128/CMR.00034-13 URL pmid: 24396134
[52]	Wang YT, Chee CB, Hsu LY, et al. Ministry of Health Clinical Practice Guidelines: Prevention, Diagnosis and Management of Tuberculosis. Singapore Med J, 2016, 57(3):118-124, quiz 125. doi: 10.11622/smedj.2016051. doi: 10.11622/smedj.2016051 URL pmid: 26996216
[53]	Lalvani A, Millington KA. T Cells and Tuberculosis: Beyond Interferon-gamma. J Infect Dis, 2008,197(7):941-943. doi: 10.1086/529049. doi: 10.1086/529049 URL pmid: 18419531
[54]	van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med, 1999,341(16):1174-1179. doi: 10.1056/NEJM199910143411602. doi: 10.1056/NEJM199910143411602 URL pmid: 10519895
[55]	Lillebaek T, Dirksen A, Vynnycky E, et al. Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J Infect Dis, 2003,188(7):1032-1039. doi: 10.1086/378240. doi: 10.1086/jid.2003.188.issue-7 URL
[56]	Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis, 1979,119(5):827-830. doi: 10.1164/arrd.1979.119.5.827. doi: 10.1164/arrd.1979.119.5.827 URL pmid: 453704
[57]	Hermans SM, Grant AD, Chihota V, et al. The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med, 2016,14:45. doi: 10.1186/s12916-016-0589-3. doi: 10.1186/s12916-016-0589-3 URL pmid: 27004413
[58]	Churchyard GJ, Fielding KL, Grant AD. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med, 2014,370(17):1662-1663. doi: 10.1056/NEJMc1402073. doi: 10.1056/NEJMc1402073 URL pmid: 24758626
[59]	刘其会, 孙峰, 张文宏. 结核病的辅助免疫治疗研究进展. 中华实验和临床感染病杂志(电子版), 2015,9(3):305-308. doi: 10.3877/cma.j.issn.1674-1358.2015.03.002.
[60]	赵爱华, 王国治, 徐苗. 我国结核病免疫学预防、治疗与诊断用制品发展进程与展望. 中国防痨杂志, 2019,41(11):1149-1154. doi: 10.3969/j.issn.1000-6621.2019.11.002.
[61]	Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019,381(25):2429-2439. doi: 10.1056/NEJMoa1909953. doi: 10.1056/NEJMoa1909953 URL pmid: 31661198
[62]	Qiu X, Tang Y, Zou R, et al. Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis. Sci Rep, 2019,9(1):11408. doi: 10.1038/s41598-019-47923-w. doi: 10.1038/s41598-019-47923-w URL pmid: 31388072
[63]	杨永林, 杨爱玲, 马强. γ干扰素诱导蛋白10对活动性结核和潜伏性结核感染的鉴别诊断价值的系统评价和meta分析. 国际检验医学杂志, 2019,40(23):2832-2836, 2840. doi: 10.3969/j.issn.1673-4130.2019.23.004.
[64]	Chegou NN, Black GF, Kidd M, et al. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med, 2009,9:21. doi: 10.1186/1471-2466-9-21. doi: 10.1186/1471-2466-9-21 URL pmid: 19445695
[65]	Walzl G, Haks MC, Joosten SA, et al. Clinical immunology and multiplex biomarkers of human tuberculosis. Cold Spring Harb Perspect Med, 2014,5(4):a018515. doi: 10.1101/cshperspect.a018515. doi: 10.1101/cshperspect.a018515 URL pmid: 25475107
[66]	Wang S, Li Y, Shen Y, et al. Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB. J Transl Med, 2018,16(1):206. doi: 10.1186/s12967-018-1572-x. doi: 10.1186/s12967-018-1572-x URL pmid: 30029650
[67]	高谦, 梅建, 谭卫国. 实事求是抓住核心脚踏实地精准防控. 中国防痨杂志, 2019,41(10):1074-1079. doi: 10.3969/j.issn.1000-6621.2019.10.002.
[68]	张璐. 崇明岛2003—2005年结核病分子流行病学研究. 上海: 复旦大学, 2007. doi: 10.7666/d.y1965474.
[69]	LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis, 2017,17(10):e327-e333. doi: 10.1016/S1473-3099(17)30248-7. doi: 10.1016/S1473-3099(17)30248-7 URL pmid: 28495525
[70]	Zak DE, Penn Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, 2016,387(10035):2312-2322. doi: 10.1016/S0140-6736(15)01316-1. doi: 10.1016/S0140-6736(15)01316-1 URL pmid: 27017310
[71]	Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. Int J Infect Dis, 2020,92S:S37-S40. doi: 10.1016/j.ijid.2020.02.034. doi: 10.1016/j.ijid.2020.02.034 URL pmid: 32114201

世界卫生组织区域	全部LTBI		近期(2年内)LTBI
世界卫生组织区域	感染率(%)	儿童(<15岁)占全部LTBI者的比率(%)	感染率(%)	耐异烟肼者占 LTBI者的比率(%)
非洲区	22.4(20.6~24.6)	13.3(11.8~14.6)	1.5(1.3~1.7)	7.4(6.4~8.7)
美洲区	11.0(7.0~20.0)	2.3(1.3~3.7)	0.2(0.1~0.2)	7.0(6.0~8.8)
东南亚区	30.8(28.3~34.8)	7.4(6.3~8.2)	1.2(0.9~1.6)	9.5(8.8~10.3)
东地中海区	16.3(13.4~20.5)	7.9(6.0~9.4)	0.7(0.5~1.0)	13.1(10.0~15.5)
西太平洋区	27.9(19.3~40.1)	2.4(1.7~3.5)	0.5(0.4~0.7)	14.7(13.9~15.6)
欧洲区	13.7(9.8~19.8)	2.0(1.3~2.7)	0.3(0.2~0.3)	29.5(23.8~45.1)
全球	23.0(20.4~26.4)	5.9(5.1~6.7)	0.8(0.7~0.9)	10.9(10.2~11.8)

第一作者	发表时间(年)	检测人群	检测方法(cut-off值)	检出率(%)(阳性例数/总例数)
全国结核病流行病学抽样调查技术指导组^[7]	2002	全人口	TST(≥6mm)	44.5(29557/66546)
刘贤政^[8]	2004	部队官兵	TST(≥5mm)	26.7(34985/131270)
He^[9]	2010	结核病防治专业人员	TST(≥10mm)	55.6(432/777)
Zhang^[10]	2013	结核病防治专业人员	T-SPOT.TB	33.6(254/755)
Zhang^[11]	2013	医务人员	T-SPOT.TB	28.7(29/101)
林涛^[12]	2011	小学生	T-SPOT.TB	3.39(16/472)
Hu^[13]	2013	儿童、青少年	T-SPOT.TB	4.702(52/1106)
郭建丽^[14]	2006	大学生	TST(≥5mm)	51.99(54719/105239)
陈莉莉^[15]	2018	大学生密切接触者	QFT-GIT	9.812(47/479)
Hu^[16]	2012	密切接触者	T-SPOT.TB	29.62(287/969)
王海英^[17]	2009	监狱羁押人员	T-SPOT.TB	27.56(86/312)
Li^[18]	2017	城市农民工	QFT-GIT	17.87(790/4422)
Gao^[19]	2015	农村人口	QFT-GIT	18.81(3955/21022)
张馨赟^[20]	2014	云南HIV感染者	T-SPOT.TB	64.3(45/70)
张馨赟^[20]	2014	上海HIV感染者	T-SPOT.TB	20.8(14/67)

治疗方案药品	成年人剂量(mg/次)		儿童剂量		用法	疗程
治疗方案药品	体质量<50kg者	体质量≥50kg者	单次剂量(mg/kg)	最大剂量(mg/次)	用法	疗程
单用异烟肼					1次/d	6~9个月
异烟肼	300	300	10	300
异烟肼、利福喷丁联合					2次/周	3个月
异烟肼	500	600	10~15	300
利福喷丁	450	600	10(>5岁)	450(>5岁)
异烟肼、利福平联合					1次/d	3个月
异烟肼	300	300	10	300
利福平	450	600	10	450
单用利福平					1次/d	4个月
利福平	450	600	10	450